Oghenowede Eyawo1,2, Yanhong Deng3, James Dziura3, Amy C Justice2,4,5, Kathleen McGinnis2, Janet P Tate2,4, Maria C Rodriguez-Barradas6, Nathan B Hansen5,7, Stephen A Maisto8, Vincent C Marconi9, Patrick G O'Connor4, Kendall Bryant10, David A Fiellin4,5, E Jennifer Edelman4,5. 1. School of Global Health, Faculty of Health, York University, Toronto, ON, Canada. 2. Veterans Aging Cohort Study Coordinating Center, (OE, ACJ, KM, JPT), West Haven VA Healthcare System, West Haven, Connecticut. 3. Yale Center for Analytic Sciences, (YD, JD), Yale University School of Public Health, New Haven, Connecticut. 4. Yale School of Medicine, (ACJ, JPT, PGO, DAF, EJE), New Haven, Connecticut. 5. Center for Interdisciplinary Research on AIDS, (ACJ, NBH, DAF, EJE), Yale School of Public Health, New Haven, Connecticut. 6. Michael E DeBakey Veterans Affairs Medical Center, (MCR-B), Baylor College of Medicine, Houston, Texas. 7. College of Public Health, (NBH), University of Georgia, Athens, Georgia. 8. Department of Psychology, (SAM), Syracuse University, Syracuse, New York. 9. Atlanta Veterans Affairs Medical Center, (VCM), Emory University School of Medicine, Atlanta, Georgia. 10. National Institute on Alcohol Abuse and Alcoholism HIV/AIDS Program, (KB), Bethesda, Maryland.
Abstract
BACKGROUND: We sought to compare self-reported alcohol consumption using Timeline Followback (TLFB) to biomarker-based evidence of significant alcohol use (phosphatidylethanol [PEth] > 20 ng/ml). Using data from patients with HIV (PWH) entering a clinical trial, we asked whether TLFB could predict PEth > 20 ng/ml and assessed the magnitude of association between TLFB and PEth level. METHODS: We defined unhealthy alcohol use as any alcohol use in the presence of liver disease, at-risk drinking, or alcohol use disorder. Self-reported alcohol use obtained from TLFB interview was assessed as mean number of drinks/day and number of heavy drinking days over the past 21 days. Dried blood spot samples for PEth were collected at the interview. We used logistic regression to predict PEth > 20 ng/ml and Spearman correlation to quantify the association with PEth, both as a function of TLFB. RESULTS: Among 282 individuals (99% men) in the analytic sample, approximately two-thirds (69%) of individuals had PEth > 20 ng/ml. The proportion with PEth > 20 ng/ml increased with increasing levels of self-reported alcohol use; of the 190 patients with either at-risk drinking or alcohol use disorder based on self-report, 82% had PEth > 20 ng/ml. Discrimination was better with number of drinks per day than heavy drinking days (AUC: 0.80 [95% CI: 0.74 to 0.85] vs. 0.74 [95% CI: 0.68 to 0.80]). The number of drinks per day and PEth were significantly and positively correlated across all levels of alcohol use (Spearman's R ranged from 0.29 to 0.56, all p values < 0.01). CONCLUSIONS: In this sample of PWH entering a clinical trial, mean numbers of drinks per day discriminated individuals with evidence of significant alcohol use by PEth. PEth complements self-report to improve identification of self-reported unhealthy alcohol use among PWH.
BACKGROUND: We sought to compare self-reported alcohol consumption using Timeline Followback (TLFB) to biomarker-based evidence of significant alcohol use (phosphatidylethanol [PEth] > 20 ng/ml). Using data from patients with HIV (PWH) entering a clinical trial, we asked whether TLFB could predict PEth > 20 ng/ml and assessed the magnitude of association between TLFB and PEth level. METHODS: We defined unhealthy alcohol use as any alcohol use in the presence of liver disease, at-risk drinking, or alcohol use disorder. Self-reported alcohol use obtained from TLFB interview was assessed as mean number of drinks/day and number of heavy drinking days over the past 21 days. Dried blood spot samples for PEth were collected at the interview. We used logistic regression to predict PEth > 20 ng/ml and Spearman correlation to quantify the association with PEth, both as a function of TLFB. RESULTS: Among 282 individuals (99% men) in the analytic sample, approximately two-thirds (69%) of individuals had PEth > 20 ng/ml. The proportion with PEth > 20 ng/ml increased with increasing levels of self-reported alcohol use; of the 190 patients with either at-risk drinking or alcohol use disorder based on self-report, 82% had PEth > 20 ng/ml. Discrimination was better with number of drinks per day than heavy drinking days (AUC: 0.80 [95% CI: 0.74 to 0.85] vs. 0.74 [95% CI: 0.68 to 0.80]). The number of drinks per day and PEth were significantly and positively correlated across all levels of alcohol use (Spearman's R ranged from 0.29 to 0.56, all p values < 0.01). CONCLUSIONS: In this sample of PWH entering a clinical trial, mean numbers of drinks per day discriminated individuals with evidence of significant alcohol use by PEth. PEth complements self-report to improve identification of self-reported unhealthy alcohol use among PWH.
Authors: Seth C Kalichman; Christina M Amaral; Denise White; Connie Swetsze; Moira O Kalichman; Chauncey Cherry; Lisa Eaton Journal: J Assoc Nurses AIDS Care Date: 2012-03-14 Impact factor: 1.354
Authors: Anders Isaksson; Lisa Walther; Therese Hansson; Anders Andersson; Christer Alling Journal: Drug Test Anal Date: 2011-03-25 Impact factor: 3.345
Authors: E Jennifer Edelman; Stephen A Maisto; Nathan B Hansen; Christopher J Cutter; James Dziura; Yanhong Deng; Lynn E Fiellin; Patrick G O'Connor; Roger Bedimo; Cynthia L Gibert; Vincent C Marconi; David Rimland; Maria C Rodriguez-Barradas; Michael S Simberkoff; Janet P Tate; Amy C Justice; Kendall J Bryant; David A Fiellin Journal: J Subst Abuse Treat Date: 2019-08-17
Authors: Friedrich M Wurst; Natasha Thon; Michel Yegles; Alexandra Schrück; Ulrich W Preuss; Wolfgang Weinmann Journal: Alcohol Clin Exp Res Date: 2015-09-07 Impact factor: 3.455
Authors: Judith A Hahn; Robin Fatch; Jane Kabami; Bernard Mayanja; Nneka I Emenyonu; Jeffrey Martin; David R Bangsberg Journal: J Acquir Immune Defic Syndr Date: 2012-12-01 Impact factor: 3.731
Authors: Emily C Williams; Kathleen A McGinnis; E Jennifer Edelman; Theresa E Matson; Adam J Gordon; Brandon D L Marshall; Kendall J Bryant; Anna D Rubinsky; Gwen T Lapham; Derek D Satre; Julie E Richards; Sheryl L Catz; David A Fiellin; Amy C Justice; Katharine A Bradley Journal: AIDS Behav Date: 2019-01
Authors: D Bhattacharjee; S Vracar; R A Round; P G Nightingale; J A Williams; G V Gkoutos; I M Stratton; R Parker; S D Luzio; J Webber; S E Manley; G A Roberts; S Ghosh Journal: Diabet Med Date: 2019-04-30 Impact factor: 4.359
Authors: Kathleen A McGinnis; Janet P Tate; Kendall J Bryant; Amy C Justice; Patrick G O'Connor; Maria C Rodriguez-Barradas; Stephen Crystal; Christopher J Cutter; Nathan B Hansen; Stephen A Maisto; Vincent C Marconi; Emily C Williams; Robert L Cook; Adam J Gordon; Kirsha S Gordon; Oghenowede Eyawo; E Jennifer Edelman; David A Fiellin Journal: AIDS Behav Date: 2021-09-20
Authors: Nicole D Fitzgerald; Yiyang Liu; Anna Wang; Catherine W Striley; Barry Setlow; Lori Knackstedt; Linda B Cottler Journal: Int J Methods Psychiatr Res Date: 2022-06-09 Impact factor: 4.182